Disclosure: This site may earn affiliate commissions when you click provider links. This doesn't affect our recommendations. Learn more
How GLP-1 telehealth prices moved from May to October 2026, from RxPickr's verified dataset: the compounded semaglutide floor fell from $149 to $133/mo, Mochi and Shed reshaped it in August and September, and Eden dropped its membership in October.
GLP-1 telehealth prices moved in one direction this spring: down, and toward simpler structures. That is the short version of what RxPickr's pricing dataset shows between our May 2026 baseline and our July 2026 refresh. We track roughly 100 individual medication offerings across 18 providers (16 telehealth platforms plus the two manufacturer-direct programs, LillyDirect and NovoCare Pharmacy), and we verify every price against the provider's own public pricing pages or a completed intake quote. Snapshots are taken monthly. This is a running tracker: the original article below covers what changed between May 4–8 and July 6, 2026, provider by provider, and we've added September and October 2026 updates at the top covering what moved since July. For the current cheapest options right now, see Cheapest GLP-1 Online in October 2026.
The headline findings:
GLP-1 medications require a prescription, so every price here assumes a licensed provider approves treatment for you. For the current cheapest options, see Cheapest GLP-1 Online in October 2026; for live rates, the pricing tool updates as providers change.
Answer 10 questions and get a personalized recommendation.
Take the free quiz →The September-to-October window (refresh completed October 7, 2026) had fewer movers than the summer, but it produced the largest single cut to a compounded monthly total we have recorded: Eden dropped its membership for compounded medication. Lilly also put two Foundayo doses on a temporary price cut, and Noom Med's microdose promo ended.
| Provider | September 2026 | October 2026 | What happened |
|---|---|---|---|
| Eden | Compounded semaglutide $99/mo and tirzepatide $199/mo medication, plus a $99/mo membership ($39 first month). Totals: about $198 and $298 | Compounded semaglutide $99/mo and tirzepatide $129/mo, all-inclusive, no membership fee and no intro rate, same price at every dose. Eden also advertises a lifetime price guarantee. Brand Wegovy ($1,695/mo) and Zepbound ($1,399/mo) unchanged and still require the $99/mo membership | Provider change: membership dropped for compounded medication. Totals down about $99/mo (semaglutide) and $169/mo (tirzepatide). Eden is now the lowest month-to-month compounded semaglutide and tirzepatide price we track. |
| LillyDirect | Foundayo $149 (0.8mg), $199 (2.5mg), $299 (5.5mg and 9mg), $349 at 14.5/17.2mg or $299 with a 45-day refill (carried from May) | Foundayo $149 (0.8mg), $149 (2.5mg), $199 (5.5mg), $299 (9mg), $299 at 14.5/17.2mg with a refill within 45 days. Zepbound unchanged at $299/$399/$449, with missed-refill prices now listed at $499 (7.5mg) and $699 (10–15mg) | Provider change: Lilly lists the 2.5mg and 5.5mg prices as temporarily reduced through December 31, 2026 (regularly $199 and $299). Ro passes the same promo prices through, plus its membership. The Foundayo ladder was re-verified this cycle for the first time since May. |
| Noom Med | Microdose $49 first four weeks, $179/mo ongoing | Microdose $79 to start (an initial 3-week subscription plus the first 4 weeks of medication, labeled a limited-time offer), $179/mo ongoing | Provider change: the $49 promo ended. Entry cost up $30; ongoing rate unchanged. |
| Mochi Health | $79/mo membership ($39 first month) | $79/mo membership ($0 first month for new members on the 1-month plan); prepaid membership $207 (3 months), $354 (6 months), $588 (12 months) | Provider change: cheaper first month. Medication prices unchanged. |
| WeightWatchers Clinic | Zepbound $299/$399/$449 within Lilly's 45-day refill window; out-of-window prices not in our records | Out-of-window Zepbound prices now recorded: $599 (7.5mg), $699 (10mg), $849 (12.5mg), $1,049 (15mg). Wegovy 7.2mg pen at $399/mo | Data clarification, not a price change. |
Re-confirmed unchanged on their own pages this cycle: Ro, Hims, Found, Shed, Henry Meds, Enhance.MD (first-month promo wording updated, prices unchanged), WeightWatchers Clinic, NovoCare, LillyDirect's Zepbound ladder, Mochi Health's medication prices, and Noom Med's ongoing rates. Carried forward from our September 1 check because their sites blocked this cycle's checks: Hers, Oak Longevity, bmiMD, TrimRx, and MEDVi's compounded prices. PlushCare's Zepbound and Wegovy figures are carried from May.
Eden's change resets the floor described in the original article below. At $99/month all-in, month to month, Eden's compounded semaglutide now undercuts the $133 Oak Longevity rate that set the July floor, and that $133 required a 3-month supply. Eden's $129 tirzepatide is the lowest compounded tirzepatide total we track. Compounded semaglutide and tirzepatide are not FDA-approved as finished products, regardless of how a provider prices them.
Eden
Compounded semaglutide $99/mo, tirzepatide $129/mo, all-inclusive with no membership fee
Dropped its membership for compounded medication in October. Month to month, same price at every dose.
The July-to-September window brought a bigger structural shift than May-to-July did: two providers rebuilt how they price their compounded catalog, two cut their published rates, one manufacturer promo expired on schedule, and both Hims and NovoCare added a new oral off-label option. Unlike the May-to-July window, brand-name pricing moved too, though only at the providers reselling it, not at the manufacturers.
| Provider | July 2026 | September 2026 | What happened |
|---|---|---|---|
| Mochi Health | Flat $99/mo compounded semaglutide, $199/mo compounded tirzepatide, plus its $79/mo membership | Per-dose ladder: semaglutide $60/mo (0.22mg) to $99/mo (2.67mg), tirzepatide $90/mo (2.2mg) to $199/mo (16.6mg), membership unchanged. Added a compounded semaglutide pill and a full brand-name catalog (Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo). | Provider change: retired flat pricing for a dose ladder. The top of each ladder matches the old flat rate, so patients titrating up pay less early and maintenance-dose patients pay about what they did before. |
| Shed | Compounded semaglutide $249/$199/$175/mo (month-to-month / 6-month / 12-month); compounded tirzepatide $349/$279/$245/mo | Semaglutide $199/$179/$159/mo; tirzepatide $299/$269/$239/mo | Provider change: price cuts across every plan length on both compounded injectables. Everything else (lozenges, drops, microdose, brand-name catalog) held steady. |
| Noom Med | Microdose semaglutide $79 first month, $199/mo ongoing; full-dose Standard $129 first month, $279/mo ongoing | Microdose $49 first month, $179/mo ongoing; full-dose $129 first month, $249/mo ongoing | Provider change: cheaper microdose and full-dose programs for new accounts since late July. Compounded tirzepatide ($149/$299) unchanged; branded-medication telehealth fee restructured from a flat $69/mo to $39 first month then $129/mo. |
| NovoCare Pharmacy | Wegovy pill $149/mo at both the 1.5mg and 4mg doses | Wegovy pill $149/mo at 1.5mg only; $199/mo at 4mg, $299/mo at 9mg or 25mg. New Ozempic Pill (oral) added at $149/$199/$299 by dose. | Provider change: the $149-for-4mg promo ended August 31, 2026, as scheduled. The Wegovy pen's $199 intro tier (0.25/0.5mg, first two fills) was extended through December 31, 2026. |
| Ro | Described on Ro's pricing page as "$149 first month" for the Wegovy pill, escalating to $199–$299/mo ongoing | Ro's current pricing page shows the Wegovy pill was priced by dose all along ($149/$199/$299), matching Hims. The Wegovy pen keeps a genuine time-limited promo: $199/mo on the two starter doses, then $349–$399/mo. New Ozempic listing added at roughly $900–$1,100/mo (near-retail, not a discounted self-pay rate). | Data clarification, not a price increase: reading Ro's current dose-by-dose table shows the pill's "first month" framing in our July notes was imprecise. Ro's membership also gained lower prepay tiers ($99 on 3-month, $89 on 6-month, alongside the existing $74 on 12-month). |
| Found | Compounded plan $169/mo (12-month) / $289/mo (monthly), medication included; brand Wegovy and Zepbound estimated at $198–$348/mo from a May 2026 intake quote, plus a $99/mo membership | Compounded plan unchanged and re-confirmed live. Brand Wegovy and Zepbound now listed only as "from $650/mo+" with no dose breakdown; CORE membership for brand-name medication is $129/mo month-to-month (~$99/mo on a 6-month prepay). | Provider change: Found's brand-name pricing got less transparent and its membership went up; compounded pricing, still the provider's core offer, is untouched. Treat Found's brand figures as unconfirmed pending checkout. |
| Hims | Wegovy pill $149/mo, pen $199/mo, Zepbound $299/mo, Foundayo $149/mo, Ozempic $199/mo, $149/mo membership | Same prices confirmed live in browser, plus a new oral Ozempic Pill at $149/mo | Provider change: added an oral off-label option; no price movement on the rest of the catalog. |
| bmiMD | Compounded semaglutide $289/mo flat, tirzepatide $399/mo flat (May figures) | Semaglutide $119/$129/$149/$159/mo on 12/6/3/1-month plans (list $228.60); tirzepatide $179/$189/$229/$249/mo (list $349.20); same price at every dose, no membership | Deep cut and a move to plan-length tiers, labeled a limited-time sale, so it may revert. |
| Oak Longevity | Semaglutide from $133/mo, tirzepatide from $199/mo on a multi-month plan (July browser read) | Confirmed on the checkout menu: $133 / $199 are the 3-month-supply rates with code OAKSAVE200; $200 / $250 month to month. Brand Wegovy $1,400, Zepbound $1,250, Ozempic $1,150, Mounjaro $1,100 also sold | No price change; structure clarified. FAQ warns dose steps may add $50–$75. |
Nine providers were re-confirmed unchanged in the September refresh: Eden ($99/mo semaglutide, $199/mo tirzepatide, $99/mo membership), TrimRx ($199/$349 flat, all-inclusive), Henry Meds (all five programs), Enhance.MD ($212/$280/$169, plus a new $322/mo Elite combo tier), LillyDirect (Zepbound ladder), WeightWatchers Clinic (Wegovy pen and Zepbound; a new oral Wegovy pill was added at $299/mo), and (with lower confidence, carried from earlier snapshots because their sites blocked this cycle's automated and browser checks) Hers, MEDVi, and bmiMD. Oak Longevity's checkout menu was opened live this cycle and its pricing structure is now confirmed (see the September update below), so it is no longer a carried figure. Compounded semaglutide is not FDA-approved as a finished product, regardless of how a provider prices it.
Shed
Compounded semaglutide from $159/mo and tirzepatide from $239/mo (12-month plan); $199 and $299 month to month
Cut both compounded injectables at every plan length in September. All-inclusive, no membership, and one price at every dose.
The table below covers every material movement between the two snapshots. We separate genuine provider-side changes from corrections to our own records, because a stale figure we fixed is not the same thing as a provider raising a price. All figures are self-pay monthly rates; "total" means medication plus any required membership.
| Provider | May 2026 (our records) | July 2026 (verified) | What happened |
|---|---|---|---|
| Found | Compounded sema $149 + $99 membership ($248 total); compounded tirzepatide $249 + $99 ($348 total) | $169/mo all-in, medication included, same price for sema, tirzepatide, and liraglutide (12-month plan; ~$199 on 6-month, $289 month to month) | Provider change: membership dropped, split billing replaced by one all-in plan. Down $79–$179/mo. |
| Eden | Sema $209/mo all-in ongoing ($129 intro); tirzepatide $329/mo | $99/mo sema, $199/mo tirzepatide medication, flat at every dose, plus a new $99/mo membership ($39 first month). Totals: $198 sema, $298 tirzepatide | Provider change: membership added, medication price flattened. Totals down slightly. |
| Oak Longevity | Sema $183/mo starter, tirzepatide $250/mo starter, each dose step adding roughly $50–$75 | Sema from $133/mo, tirzepatide from $199/mo, one flat price at every dose (multi-month plan; sema runs about $167–$199 month to month) | Provider change: dose-escalation pricing replaced with flat all-dose rates. Down, especially at maintenance doses. |
| Shed | Sema lozenges $299/mo; sema drops $329/mo and tirzepatide drops $419/mo | Lozenges $199/mo; drops consolidated into a single $229/mo GLP-1 Liquid Drops product | Provider change: non-injection formats cut $100–$190/mo. Injectables confirmed unchanged. |
| Noom Med | Microdose first month $99, then $199/mo | Microdose first month $79, then $199/mo | Provider change: intro price cut $20. Ongoing rate unchanged. |
| Enhance.MD | $49 first month (sema) and $99 first month (tirzepatide) on 12-month plans | Flat first-month promos retired, replaced by seasonal discount codes. Ongoing rates unchanged: $212 sema, $280 tirzepatide, $169 Microdose Tirzepatide | Provider change: entry cost up. The only increase in this cycle. |
| Ro | Compounded semaglutide listed (price gated behind account) | Compounded semaglutide discontinued; brand-name only | Provider change: catalog exit, following Hims' earlier move to brand-only. |
| TrimRx | Sema $179/mo, tirzepatide $259/mo | Sema $199/mo flat all-inclusive, tirzepatide $349/mo flat all-inclusive, $0 membership | Data correction: the $179 was a first-month rate and the $259 matched no current tier. Not a confirmed provider increase. |
| NovoCare Pharmacy | Ozempic $349/mo labeled as a starter price | $199/mo for the first two months, then $349/mo ongoing ($499 for the 2mg dose) | Data correction: our record mislabeled the ongoing price and missed the intro tier (per NovoCare Ozempic offer page, July 2026). |
| Shed (brand) | Wegovy pen $149 + $125 membership; Zepbound $299 + $125 | Wegovy pen $199 + $125; Zepbound from $349 + $125 (by dose) | Data correction: the pen had been recorded at the pill's price. Wegovy pill $149 and $125 membership confirmed correct. |
| Eden (brand) | Wegovy $199, Zepbound $299 (estimates) | Wegovy $1,695/mo, Zepbound $1,399/mo cash retail, plus membership | Data correction: prior figures were manufacturer-program estimates, not Eden's own cash prices. |
Nine providers were confirmed unchanged in the July refresh: LillyDirect (Zepbound vials $299/$449 by dose, Foundayo $149–$349 ladder), NovoCare (Wegovy pill $149/mo; the Ozempic row in the table above corrected our record, not a Novo price change), PlushCare ($19.99/mo membership, brand-only), Mochi Health ($79 membership + $99 sema / $199 tirzepatide), Henry Meds (all five offerings, including the $179/mo sublingual sema), Hims ($149–$299 brand catalog + $149 membership), Hers (Zepbound vial $299 confirmed), bmiMD ($289 sema / $399 tirzepatide), and WeightWatchers Clinic ($74 membership, Wegovy $349 self-pay). MEDVi's public prices ($179 first month, $299 refill) were also re-confirmed, though its tirzepatide figure remains an estimate.
The most visible structural shift this cycle is the death of the dose ladder among compounded providers. In May, Oak Longevity priced compounded semaglutide at $183/month for the starter dose with each titration step adding roughly $50–$75, so a patient reaching a maintenance dose paid meaningfully more than the headline. By July, Oak had moved to one flat price at every dose: semaglutide from $133/month, tirzepatide from $199/month.
Oak now joins TrimRx ($199 sema, $349 tirzepatide, flat across doses, no membership), Enhance.MD (same price at every dose), Eden (flat medication price at every dose), and Found (one plan price across compounded drugs and doses) in advertising dose-independent pricing. That is five of the 11 compounded semaglutide sellers we track.
This matters for buyers because dose-escalation pricing quietly raised real-world costs 3 to 6 months in, exactly when most patients titrate up. Flat pricing appears to be a competitive response to that pain point, though we can only observe the pricing pages, not the strategy behind them. If you compared providers in the spring using starter-dose prices, the ranking at maintenance doses looks different now.
Two providers rebuilt their billing structure between snapshots, and they moved in opposite directions.
Found retired its split model, where a $149/month compounded medication charge stacked on a $99/month membership for a $248/month real total. Its GLP-1 Program now bundles the medication into one plan price: $169/month on the 12-month plan, about $199/month on the 6-month plan, and $289/month month to month, verified on Found's plans-and-pricing page in July 2026. At the low end that is $79/month cheaper than the May structure, and the quoted number is finally the number you pay.
Eden went the other way. It introduced a $99/month membership ($39 the first month) on top of medication prices that it simultaneously flattened to $99/month for semaglutide and $199/month for tirzepatide at every dose. The effective totals ($198 and $298) actually came down slightly from May's $209 and $329 all-in rates, but the advertised medication price no longer equals the real total.
The lesson from watching both moves side by side: a "medication price" and a "monthly total" are different numbers, and providers shift costs between the two lines. Our dataset and pricing tool always record both.
Found
From $169/mo all-in (compounded medication included, 12-month plan)
Dropped its separate membership this cycle. The biggest single price decline in our May-to-July data: $248/mo total down to $169/mo.
Split the dataset into compounded and brand-name offerings and the contrast is stark. On the compounded side, every confirmed provider-side change to a recurring rate between May and July moved down or restructured flat: Found (down $79–$179/month in total), Eden (totals down $11–$31/month), Oak (headline down $50/month with the escalation ladder removed), and Shed (non-injection formats down $100–$190/month). The only upward movement was Enhance.MD retiring its first-month promos, an entry-cost change that left ongoing rates untouched.
On the brand side, nothing moved. LillyDirect, NovoCare, Hims, Hers, PlushCare, and WeightWatchers Clinic all reconfirmed their May brand pricing in July. Manufacturer self-pay programs appear to reprice on their own calendar (Lilly's current Zepbound vial tiers date to December 2025, per LillyDirect), not in response to month-to-month telehealth competition.
The compression is sharpest in compounded tirzepatide. In May, the category ran $169–$449/month and every provider priced tirzepatide well above semaglutide. By July the band was $169–$399, and at Found the premium disappeared entirely: compounded tirzepatide costs the same $169/month as semaglutide. Eden's gap narrowed from $120 to $100/month, and Oak's flat rates hold the gap to $66/month at every dose, where its old escalation model let both drugs climb. This is consistent with easier active-ingredient sourcing or simple price competition, but that is our reading of the numbers, not something any provider has stated.
One structural caveat belongs in any analysis of compounded pricing: compounded GLP-1 medications are made by licensed compounding pharmacies and are not FDA-approved as finished products. They contain the same active ingredient as the brand drug, but the finished formulation has not been reviewed by the FDA for safety, efficacy, or quality (FDA, 2025). Regulatory change here could reshape the price picture faster than any competitive dynamic. Ro's exit from compounded semaglutide this cycle, following Hims' move to brand-only after its agreement with Novo Nordisk, shows the large platforms already consolidating around FDA-approved products.
Two FDA-approved oral products now sit at $149/month direct from their manufacturers: Foundayo (orforglipron), which the FDA approved on April 1, 2026 as the first oral GLP-1 receptor agonist without food and water restrictions (FDA, April 2026), at $149/month for the 0.8mg starter dose via LillyDirect, and the Wegovy pill at $149/month (1.5mg and 4mg doses) via NovoCare Pharmacy.
Both are fulfillment-only programs: you bring your own prescription, and there is no telehealth visit or care team included. But their existence appears to function as a ceiling on what compounded providers can charge at entry. It is probably not a coincidence that the compounded semaglutide floor moved from $149 to $133 in the same window, and that Eden now advertises a $99/month medication price. When an FDA-approved pill costs $149 direct, a compounded product, which is not FDA-approved as a finished product, has to be visibly cheaper to make its case. Note that Foundayo's own ladder still escalates by dose, reaching $349/month at the top, so the anchor holds at entry doses more than at maintenance.
The table below pulls from our live dataset, the same data behind the pricing tool, so it reflects the current verified state rather than the snapshot this article froze in time.
| Provider | Monthly cost |
|---|---|
| Eden | $99/mo |
| bmiMD | $119/mo |
| Oak Longevity | $133/mo |
| Mochi Health | $139/mo |
| Mochi Health | $141/mo |
| Shed | $149/mo |
| Shed | $159/mo |
| Found | $169/mo |
| Noom Med | $179/mo |
| Henry Meds | $179/mo |
| TrimRx | $199/mo |
| Shed | $199/mo |
| Enhance.MD | $212/mo |
| Shed | $229/mo |
| Oak Longevity | $245/mo |
| Noom Med | $249/mo |
| Henry Meds | $249/mo |
| Henry Meds | $297/mo |
| MEDVi | $299/mo |
| MEDVi | $369/mo |
Prices reflect self-pay out-of-pocket cost as of 2026. Verify current pricing before purchasing.
Oak Longevity
From $133/mo (semaglutide) or $199/mo (tirzepatide), one flat price at every dose
Set the new market floor this cycle after switching to flat all-dose pricing with no membership. Multi-month plan for the best rate.
Three practical rules fall straight out of the May-to-July data.
Verify the ongoing price at checkout, not the headline. The two biggest gaps in our dataset between advertised and real prices are first-month teasers and separate memberships. MEDVi's $179 first month becomes $299 on refill. Noom Med's $79 intro becomes $179. Mochi's per-dose semaglutide ($60 to $99) carries a $79 membership, and the $99 membership Eden added in July applied to its compounded medication until it was dropped in October (it still applies to Eden's brand-name products). Before enrolling anywhere, confirm the month-two price, whether a membership bills separately, and what dose the quote covers.
Price the commitment honestly. The lowest numbers in this article, Oak's $133 and Found's $169, assume multi-month or 12-month prepaid plans. Month to month, Oak's semaglutide runs about $167–$199 and Found's plan is $289. If you are not confident you will stay on treatment past a few months, the month-to-month rate is your real price, and the ranking changes.
Recheck the market if you priced it in spring. Anyone who compared providers in May using dose-escalation starter prices, Found's split billing, or Shed's old lozenge price is working from a stale map. The October cheapest-GLP-1 breakdown has the current category-by-category winners, the pricing tool has live filterable rates, and the quiz matches you to a provider based on your budget, insurance, and medication preference.
This price history is RxPickr's own original dataset. To our knowledge no other public source tracks verified GLP-1 telehealth prices longitudinally at the offering level. Journalists, researchers, and other publishers are welcome to cite or reproduce the figures with attribution to "RxPickr GLP-1 Price Tracker" and a link to this page or the pricing tool. If you need the underlying snapshot data or have a correction, contact us; we would rather fix a number than defend it.
Snapshots. The May baseline was verified May 4–8, 2026, primarily by direct provider sign-up and pricing-page audits. The July refresh was completed July 6, 2026, with one researcher per provider re-verifying every offering against live provider pages.
Verification tiers. Most July prices were read directly from provider pricing pages loaded in a live browser session (Found, Oak, Shed, Eden, MEDVi, Noom Med, Mochi, Henry Meds, PlushCare, WeightWatchers Clinic, LillyDirect, NovoCare). A few providers block automated access to their sites, so their prices were corroborated through multiple independent 2026 third-party reviews instead (Hims, Hers, bmiMD). TrimRx's figures are third-party corroborated but not checkout-confirmed, and we label them accordingly in the dataset.
Known gaps still awaiting checkout verification. Found's brand-name medication prices are gated behind its intake survey and its membership structure for brand products changed this cycle, so those figures are provisional. The Hers Zepbound KwikPen price is unconfirmed (the pen is not part of Lilly's self-pay vial program). Enhance.MD's current promo-code first-month net prices and its combined sema-plus-tirzepatide tier are not yet priced. MEDVi publishes no tirzepatide-specific pricing, so its tirzepatide figure remains an estimate. Oak's oral semaglutide ($245) was not re-checked in July.
September update. The September 1, 2026 refresh combined a fetch-only research pass with a live browser pass for Hims, Hers, MEDVi, bmiMD, TrimRx, Oak Longevity, Found, and Shed. LillyDirect's Foundayo ladder and PlushCare's Zepbound price are carried forward from their last confirmed dates rather than presented as September-verified; the pricing tool shows the true per-entry date for each. Oak Longevity's checkout menu was opened live on September 1, 2026, confirming its $133/$199 semaglutide/tirzepatide rates as the 3-month-supply prices with checkout code OAKSAVE200 ($200/$250 month to month), plus four brand-name offerings (Mounjaro, Ozempic, Zepbound, Wegovy) at retail-level pricing; see the change table above.
October update. The October 7, 2026 refresh used a fetch-only research pass plus direct checks of every material change on the provider's own page; no live browser pass was available this cycle. LillyDirect's Foundayo ladder was re-verified, except the standard (non-refill) rate for the 14.5mg and 17.2mg doses, which Lilly no longer prints. Hers, Oak Longevity, bmiMD, TrimRx, and MEDVi's compounded prices are carried forward from September 1, 2026, and PlushCare's Zepbound and Wegovy figures from May; the pricing tool shows the true per-entry date for each. We re-verify pricing monthly.
Scope. All prices are self-pay unless noted, exclude insurance coverage and manufacturer savings-card scenarios, can vary by dose and state, and change without notice. The snapshot comparison covers roughly 100 current offerings across 18 providers; offerings we removed as data errors (rather than provider changes) are excluded from the trend counts above.